What Is the Best Surgical Margin for a Basal Cell Carcinoma: A Meta-Analysis of the Literature

University of Maryland, Baltimore, Baltimore, Maryland, United States
Plastic and Reconstructive Surgery (Impact Factor: 3.33). 10/2010; 126(4):1222-31. DOI: 10.1097/PRS.0b013e3181ea450d
Source: PubMed

ABSTRACT Current management of basal cell carcinoma is surgical excision. Most resections use predetermined surgical margins. The basis of ideal resection margins is almost completely from retrospective data and mainly from small case series. This article presents a systematic analysis from a large pool of data to provide a better basis of determining ideal surgical margin.
A systematic analysis was performed on data from 89 articles from a larger group of 973 articles selected from the PubMed database. Relevant inclusion and exclusion criteria were applied to all articles reviewed and the data were entered into a database for statistical analysis.
The total number of lesions analyzed was 16,066; size ranged from 3 to 30 mm (mean, 11.7 ± 5.9 mm). Surgical margins ranged from 1 to 10 mm (mean, 3.9 ± 1.4 mm). Negative surgical margins ranged 45 to 100 percent (mean, 86 ± 12 percent). Recurrence rates for 5-, 4-, 3-, and 2-mm surgical margins were 0.39, 1.62, 2.56, and 3.96 percent, respectively. Pooled data for incompletely excised margins have an average recurrence rate of 27 percent.
A 3-mm surgical margin can be safely used for nonmorpheaform basal cell carcinoma to attain 95 percent cure rates for lesions 2 cm or smaller. A positive pathologic margin has an average recurrence rate of 27 percent.


Available from: Ronald P Silverman, Jun 03, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Vismodegib is an oral hedgehog-pathway inhibitor approved for advanced basal cell carcinoma (BCC). Although most BCCs are amenable to surgery, excision of large tumors in aesthetically sensitive sites may compromise function or cosmesis. Objective: We sought to evaluate the reduction in BCC surgical defect area after 3 to 6 months of neoadjuvant vismodegib. Methods: This was an open-label, single-arm intervention trial with a primary outcome of change in target-tumor surgical defect area pre- and post-vismodegib (150 mg/d). Secondary outcomes were change in tumor area and tolerability. Results: Eleven of 15 enrolled patients, aged 39 to 100 years, completed the trial. Thirteen target tumors were excised after a mean of 4 6 2 months of vismodegib. In all, 29% (4 of 14 patients) could not complete more than 3 months because of vismodegib-related side effects. The mean baseline target-tumor diameter was 3.2 cm, and 10 of 13 tumors occurred on the face. Overall, vismodegib reduced the surgical defect area by 27% (95% confidence interval -45.7% to -7.9%; P = .006) from baseline. Vismodegib was not effective in patients who received less than 3 months. Over a mean follow-up of 11.5 (range 4-21) months for all tumors, only 1 tumor recurred at 17 months post-Mohs micrographic surgery. Limitations: Short follow-up time and no placebo control are limitations. Conclusion: Neoadjuvant vismodegib appears to reduce surgical defect area when taken for 3 months or longer for nonrecurrent BCCs in functionally sensitive locations. Further studies with larger sample sizes and long-term follow-up are warranted.
    Journal of the American Academy of Dermatology 06/2014; 71(5). DOI:10.1016/j.jaad.2014.05.020 · 5.00 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The aim of this study is to determine the benefits and disadvantages of using micrographic surgery in the treatment of basal cell carcinomas (BCC) of the face. We compared the classic surgery with the micrographic surgery by using a prospective randomized comparative study for two groups of patients.Methods: Patients included in the study were divided into two groups. The first group was treated by Mohs Surgery. A number of 49 patients who presented 52 tumors were included in this group. In the second group were included 52 patients with 53 tumors. These patients were treated by classic surgery. Patients were scheduled for follow-up and evaluation of efficacy of the two surgical methods.Results: The mean follow-up was one year for the micrographic surgery group and 1.1 years for the classic surgery group. For the micrographic surgery group we noted zero recurrences and for the classic surgery group we had two (3.7%) recurrences in two different patients. Treatment time (surgical excision) was 21 minutes for the classic surgery group and 47 minutes for the micrographic surgery group.Conclusions: Micrographic surgery remains the gold standard for the treatment of BCC at the head level. Micrographic surgery is the only treatment method which is reporting healing rates over 95% in the majority of studies. A good selection of the cases is mandatory; micrographic surgery should be used for aggressive tumors in difficult location and especially on the face.
    01/2013; 59(2). DOI:10.2478/amma-2013-0014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cutaneous head and neck tumors mainly comprise malignant melanoma, squamous cell carcinoma, trichoblastic carcinoma, Merkel cell carcinoma, adnexal carcinoma, dermatofibrosarcoma protuberans, sclerodermiform basalioma and angiosarcoma. Adapted management requires an experienced team with good knowledge of the various parameters relating to health status, histology, location and extension: risk factors for aggression, extension assessment, resection margin requirements, indications for specific procedures, such as lateral temporal bone resection, orbital exenteration, resection of the calvarium and meningeal envelopes, neck dissection and muscle resection. Copyright © 2014. Published by Elsevier Masson SAS.
    European Annals of Otorhinolaryngology, Head and Neck Diseases 11/2014; 131(6):375-383. DOI:10.1016/j.anorl.2014.06.002